Adeera Levin

Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design.

In both clinical research and study design, the definition of outcomes for chronic kidney disease (CKD) is changing. New molecules available for testing in humans, and the fact that kidney diseases are best treated earlier in their course, make the duration of studies requiring 'hard endpoints' longer than is feasible...